The evaluation of hyaluronic acid and laminin concentration in serum in children with chronic hepatitis B treated with lamivudine, unresponsive to previous interpheron α therapy;Ocena stȩżenia kwasu hialuronowego i lamininy w surowicy dzieci chorych na pizewlekłe zapalenie wa̧troby typu B leczonych lamiwudyna̧ po nieskutecznej terapii interferonem α

Polski Merkuriusz Lekarski

Volumn 18, Issue 105, 2005, Pages 268-270

  Skiba, Elzbieta ^a   Lebensztejn, Dariusz Marek ^a   Werpachowska, Irena ^a   Kaczmarski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children; Chronic hepatitis; HBV; Hialuronic acid; Laminin; Lamivudine

Indexed keywords

ALPHA INTERFERON; ANTIFIBROTIC AGENT; HYALURONIC ACID; LAMININ; LAMIVUDINE; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MALE; PROSPECTIVE STUDY; SERUM; BLOOD; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; INTERFERON-ALPHA; LAMININ; LAMIVUDINE; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 17144394135     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dienstag J.L. i wsp.: Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124, 105-117.
2. Gabrielli G.B. i wsp.: Serum laminin P1 in chronic viral hepatitis: correlations with histological activity and diagnostic value. Clin. Chim. Acta, 1996, 252, 171-180.
3. Guido M. i wsp.: Is liver biopsy needed in children with chronic hepatitis? Acta Gastroenterol. Bel., 1998, 61, 214-216.
4. Hagmann S. i wsp.: Response to lamivudine treatment in children with chronic hepatitis B virus infection. Clin. Infect. Dis., 2003, 37, 1434-1440.
5. Hartman C. i wsp.: Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr. Infect. Dis. J., 2003, 22, 224-229.
6. Hasegawa T. i wsp.: Measurement of serum hyaluronic acid as a sensitive marker of liver fibrosis in biliary atresia. J. Pediatr. Surg., 2000, 35, 1643-1646.
7. Jonas M.M. i wsp.: Clinical trial of lamivudine in children with chronic hepatitis B.N. Engl. J. Med., 2002, 30, 1682-1683.
8. Keam S.J., Scott L.J.: Lamivudine in children and adolescents with chronic hepatitis B virus infection. Paediatr. Drugs., 2002, 4, 687-694.
9. Kobayashi H. i wsp.: Hyaluronic acid: a specific prognostic indicator of hepatic damage in biliary atresia. J. Pediatr. Surg., 1999, 34,1791-1794.
10. Kocak N. i wsp.: Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology, 2000, 31, 545.
11. Kozlowska J. i wsp.: Value of serum determination of biochemical markers of fibrosis in patients with liver cirrhosis. Med. Sep. Monit., 1999, 5, suppl. 1, 57-61.
12. Kropf J., Gressner A.M., Negwer A.: Efficacy of serum laminin measurement for diagnosis of fibrotic liver disease. Clin. Chem., 1988, 34, 2026-2030.
13. Lebensztejn D.M.: Ocena biochemiczna i morfologiczna procesu włóknienia wajroby u dzieci z przewlekłym zapaleniem wa̧troby typu B. Rozprawa habilitacyjna. Akademia Medyczna. Białymstok. 2002.
14. Lebensztejn D.M. i wsp.: Czȩść wystaopienia zjawiska serokonwersji w układzie HBeAg/antyHBe wywołanego leczeniem lamiwudyna̧ u dzieci z przewlekłym zapaleniem wa̧troby typu B po nieskutecznej leczema interferonem α. Pol. Merk. Lek., (w druku).
15. Leung N.W. i wsp.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 2001, 33, 1527-1532.
16. Luo R. i wsp.: Diagnostic value of five serum markers for liver fibrosis. Zhonghua Gan Zang Bing Za Zhi, 2001, 9, 148-150.
17. Maharaj B. i wsp.: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet, 1986, 1, 523-525.
18. Majda-Stanislawska E.: Skuteczność 3TC w leczenia dzieci z przewlekłym zapaleniem wa̧troby typu B. Pediatr. Pol., 2001, 76, 579-584.
19. McHutchison J.G. i wsp.: Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol., 2000, 15, 945-951.
20. Murawaki Y. i wsp.: Diagnostic value of serum markers of connective tisue turnover for predicting histological staging and grading in patients with chronic hepatitis C.J. Gastroenterol., 2001, 36, 399-406.
21. Nakashima E. i wsp.: Serum level hyaluronate correlates to the degree of liver fibrosis in pediatric liver disease. Hepatol. Res., 1999, 16, 59-67.
22. Oberti F. i wsp.: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology, 1997, 113, 1609-1616.
23. Patel K. i wsp.: Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.J. Gastroenterol. Hepatol., 2003, 18, 253-257.
24. Sasaki F. i wsp.: Laminin and procollagen-III-peptide as serum marker for hepatic fibrosis in congenital biliary atresia. J. Pediatr. Surg., 1992, 27, 700-703.
25. Schuppan D. i wsp.: Serum assays for liver fibrosis. J. Hepatol., 1995, 22, suppl. 2, 82-88.
26. Suzuki Y. i wsp.: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol., 1999, 30, 743-748.
27. Trivedi P. i wsp.: Variation in serum type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis. Eur. Clin. Invest., 1985, 15, 69-74.
28. Trivedi P., Cheeseman P., Mowat A.P.: Serum hyaluronic acid in healthy infants and children and its value as a marker of progressive hepatobiliary disease starting in infancy. Clin. Chim. Acta, 1993, 215, 29-39.
29. Walsh K.M. i wsp.: Basement membrane peptides as markers of liver disease in chronic hepatitis C.J. Hepatol., 2000, 32, 325-330.
30. Wyath H.A. i wsp.: Serum hyaluronan acid concentration are increased in cystic fibrosis patients with liver disease. Arch. Dis. Child., 2002, 86, 190-193.